Affordable Access to Selexipag for Pulmonary Arterial Hypertension Patients

Breathing is considered as the most essential act of the human body. When you breathe, you live. But unfortunately, for people who are dealing with Pulmonary Arterial Hypertension (PAH), it is a challenge. 

PAH isn't just high blood pressure; it is a rare and progressive disease that can be fatal. In this blog, we share affordable options for easily accessing PAH drugs, providing hope for patients in need.

What is Pulmonary Arterial Hypertension?

PAH is a progressive and rare lung disease that can affect anyone, regardless of age. It occurs when the small blood vessels in the lungs narrow, restricting blood flow and increasing pressure in the arteries. This strain results in weakening of the heart as it struggles to pump blood, which then leads to severe complications and fatality.

What are the Medicines for PAH?

PAH is a life-threatening condition where the patient struggles to breathe. However, with proper care and suitable treatment, several patients manage symptoms and keep moving forward with PAH drugs like -

Selexipag (Uptravi®) for PAH

Selexipag is a selective prostacyclin receptor agonist used to treat Group 1 PAH pulmonary arterial hypertension (PAH). It relaxes lung blood vessels, reducing heart strain and improving physical capacity. It is sold under the brand name Uptravi®. Selexipag is necessary for many PAH patients as it helps slow disease progression and enhance quality of life, but its high cost can make long-term treatment difficult.

Why PAH Treatment Costs Remain a Challenge?

1. High cost of medications
PAH treatments often involve expensive drugs such as endothelin receptor antagonists, PDE5 inhibitors, and prostacyclin analogs, which are essential but costly.

2. Need for specialised care
Managing PAH requires experienced specialists and regular monitoring through diagnostic tests, procedures, and clinic visits, which increases the overall healthcare expenditure.

3. Long-term treatment need
PAH is a chronic and progressive condition that demands lifelong, costly treatment, continuous monitoring, and frequent adjustments in therapy.

4. Indirect economic burden
PAH impacts a patient’s ability to work, often leading to lost income, sick leave, and disability, resulting in additional financial strain and reduced quality of life.

Living with PAH and the cost of essential medicines like Selexipag can be overwhelming for people without insurance or government support.

Here’s a precise comparison table showing the cost of Selexipag (Uptravi®) across different countries vs. Medspartner’s affordable generic price. This helps patients immediately grasp the cost savings and make informed decisions-

Why Is The Generic Version Important?

Huge cost savings - Huge cost differences make the treatment available to patients facing financial stress.

Quality assurance - These generics are made by FDA/EMA-approved Indian manufacturers, assuring high quality.

Legal under importation rules - Many countries allow limited personal imports with a valid prescription and documentation.

While government subsidies under NHS/PBS and pharma assistance programs like the Janssen CarePath exist, many patients still face rejections or high out-of-pocket costs.

For those falling through the cracks, personal importation of affordable generics from other countries is a lifesaver. These alternatives can significantly lower costs, serving as the only means of viable treatment for many.

How can I Legally Import Lower-Cost Generic PAH Drugs From India?

Most countries do allow patients to import prescription medications for personal use under specific conditions-

Prescription Needed

You must have a prescription from a licensed medical practitioner for your personal use. This applies globally, including countries like the UK, US, Canada, Australia, and others.

Quantity Limits - Up to 3-Month Supply

Most countries allow up to a 90-day supply per shipment. Beyond that, it may demand special authorization.

Import for Personal Use Only (No Resale)

The medicine must be for your personal use and not resale. This is a strict rule across all countries.

Buy from Licensed, Approved Sources Only

You must import from a licensed international pharmacy with clear documentation. Suppliers should provide invoices and product details.

Online pharmacies like Medspartner source from USFDA/EMA-approved manufacturers and help with compliant documentation.

How Does Medspartner Encourage Personal Importation of Affordable Equivalents to PAH Legally?

At Medspartner, we strongly feel that every patient has the right to receive the drug they need, irrespective of the financial burden. That's why we deliver affordable, high-quality Selexipag (Uptravi®) sourced from leading manufacturers licensed by regulatory bodies like the USFDA and EMA.

We have 8+ years of experience sourcing medicines to patients through compliant personal importation and can support you every step of the way, from documentation support to timely shipping.

Affordable High-Quality Alternatives for PAH Treatment

Selexipag (Uptravi®) is a vital treatment for those living with pulmonary arterial hypertension (PAH), but we know that the cost can be a barrier for some. Fortunately, there are affordable options available in many countries through personal importation. At Medspartner, we’re here to help patients who are facing financial challenges in accessing safe and effective medications. If you need assistance in finding an affordable alternative to Uptravi®, just reach out to us, we’d love to help!

Write to us today to explore safe and affordable ways to purchase affordable versions of the drug for PAH recovery!

About the Author - Aayyush Goyal is the founder of MedsPartner, a global platform improving access to affordable, life-saving medicines. With a background in healthcare consulting and pharmaceutical supply chains, he has over a decade of experience in drug pricing, regulatory policy, and patient rights. Aayyush is a recognized advocate for ethical sourcing, generic access, and cross-border care solutions.